SEC Comment Letter 0000000000-24-003953 to Poseida Therapeutics, Inc. (CIK 0001661460)
Poseida Therapeutics, Inc. (CIK 0001661460)
Date: April 11, 2024 · CIK: 0001661460 · Accession: 0000000000-24-003953
AI Filing Summary & Sentiment
File numbers found in text: 333-278559
Letter
United States securities and exchange commission logo April 11, 2024 Kristin Yarema, Ph.D. Chief Executive Officer Poseida Therapeutics, Inc. 9390 Towne Center Drive, Suite 200 San Diego, CA 92121 Re:Poseida Therapeutics, Inc. Registration Statement on Form S-3 Filed April 8, 2024 File No. 333-278559 Dear Kristin Yarema: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Edmond Lay, Esq.
Show Raw Text
United States securities and exchange commission logo
April 11, 2024
Kristin Yarema, Ph.D.
Chief Executive Officer
Poseida Therapeutics, Inc.
9390 Towne Center Drive, Suite 200
San Diego, CA 92121
Re:Poseida Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 8, 2024
File No. 333-278559
Dear Kristin Yarema:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Edmond Lay, Esq.